Premium
Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial
Author(s) -
Guerdjikova Anna I.,
Mori Nicole,
Blom Thomas J.,
Keck Paul E.,
Williams Stephanie L.,
Welge Jeffrey A.,
McElroy Susan L.
Publication year - 2016
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.2547
Subject(s) - tolerability , placebo , binge eating , clinical endpoint , adverse effect , body mass index , population , psychology , binge eating disorder , medicine , physical therapy , randomized controlled trial , psychiatry , eating disorders , bulimia nervosa , alternative medicine , environmental health , pathology
Objective To evaluate lisdexamfetamine dimesylate (LDX) in the treatment of binge eating disorder (BED). Method Fifty participants with BED received LDX (20–70 mg/day) ( n = 25) or placebo ( n = 25) for up to 12 weeks in a single‐center, randomized, double‐blind, and flexible‐dose trial. The primary outcome measure was binge eating (BE) days/week. Results In the primary longitudinal analysis, compared with placebo, LDX was not associated with a significantly greater rate of reduction in BE days/week, as well as BE episodes/week, and scores on the Clinical Global Impression‐Severity or Yale–Brown Obsessive–Compulsive Scale modified for binge eating scales. It was, however, associated with significantly decreased weight, body mass index, and fasting triglyceride level. In the secondary last observation carried forward analyses, LDX was associated with statistically significant reductions in BE days/week, BE episodes/week, weight, and BMI, as well as a statistically significant greater level of categorical response and global improvement. The mean (standard deviation) LDX daily dose at endpoint evaluation was 59.6 (14.9) mg. One participant discontinued LDX for a serious adverse cardiovascular event, which resolved fully. Conclusion Lisdexamfetamine dimesylate may have clinical utility for BED but further studies of its efficacy, tolerability, and safety in this population are needed. Copyright © 2016 John Wiley & Sons, Ltd.